New and Emerging Therapies for Alzheimer Disease

In this AdaptED learning module, the adaptive learning algorithm will employ Alzheimer disease (AD) neuropathology as a backdrop to explore various promising mechanisms of action for new and emerging disease-modifying therapies, such as those targeting β-amyloid, tau, inflammation, central nervous system glucose metabolism, bioenergetics, and synaptic plasticity. The activity will focus on anti-amyloid antibodies in late phases of development, under FDA review, or that have recently received an FDA indication to treat AD. The education will dive into the clinical efficacy, safety, tolerability, and administration of these agents and will identify which patients are most likely to benefit from taking them.

Learning Objectives

  • Explore the mechanism of action of new and emerging disease-modifying therapies for Alzheimer disease (AD)
  • Explore the evidence supporting new and emerging disease-modifying therapies for AD and consider which patients are most likely to benefit from these therapies

Additional Information

Partner: 
Pri-Med
Course summary
Available credit: 
  • 0.50 AANP Contact Hours
  • 0.50 AANP Pharmacology Contact Hours
  • 0.50 AMA PRA Category 1 Credit™
Course opens: 
06/10/2022
Course expires: 
06/10/2023
Rating: 
0

Gad A. Marshall, MD

Associate Professor of Neurology
Harvard Medical School
Associate Medical Director of Clinical Trials
Center for Alzheimer Research and Treatment
Brigham and Women's Hospital
Assistant in Neurology
Massachusetts General Hospital
Boston, MA

Disclosures

  • Gad A. Marshall, MD: Independent Contractor for Eisai, Genentech, and Lilly.

AMA PRA Category 1 Credits™

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.

Designation Statement

This activity is approved for 0.50 contact hours of continuing education, which includes 0.50 hours of pharmacology.

Available Credit

  • 0.50 AANP Contact Hours
  • 0.50 AANP Pharmacology Contact Hours
  • 0.50 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through Pri-Med. 

To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity. 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch